RESEARCH TRIANGLE PARK, N.C. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal

- Raised $75   M illion through Underwritten Public Offering - Bolstered   and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to Host Webcast and Conference Call Today at 8:00   a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov.

Company Determines Unsolicited Offer does not Constitute Superior Proposal RESEARCH TRIANGLE PARK, N.C , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products

Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products

RESEARCH TRIANGLE PARK, N.C. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, today announced that it has

PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® RESEARCH TRIANGLE PARK, N.C. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company

Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care RESEARCH TRIANGLE PARK, N.C. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and

Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization

RESEARCH TRIANGLE PARK, N.C. , Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, today announced that it has

Steven Bariahtaris Appointed Interim Chief Financial Officer RESEARCH TRIANGLE PARK, N.C. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its